ClinicalTrials.gg
RecruitingNCT06899165Updated Aug 13, 2026

Psilocybin-Assisted Therapy for Intergenerational Trauma

A Phase 2 interventional study of Psilocybin and Integration sessions in Psychological Stress, Depression and Anxiety, sponsored by Rachel Yehuda. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Rachel Yehuda · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 290 studies in Stress, Psychological with a site in United States — 31 open to participants now, 46 under way, 1 of them phase 3. Stress, Psychological · United States.

Planned enrollment
108th of 262
100 · median 84
Started
2026
with 13 others
Phase 2
8 of 290
1 open now
Primary completion
2029-05
later than 41 of 45 live
Registered
266th of 290
by date

Among the 290 studies in Stress, Psychological with a site in United States, this one is the 108th largest by planned enrollment of the 262 interventional ones that give a count, is one of 14 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 41 of the 45 other live ones, and was the 266th registered.

Stress, Psychological

854 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

31 of the 290 studies in Stress, Psychological with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Stress, Psychological with a site in United States, or all of them as a file.
02

Study summary

This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders.

The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Read the detailed description

This study is investigating whether Psilocybin-assisted therapy improves depression, anxiety and stress symptoms in the offspring (biological children) of genocide survivors. Intergenerational trauma is the concept that the effects of experiencing extreme stress can be perpetuated to future generations. A genocide here is defined by the extinction or threat of extinction of a racial, religious or ethnic group, by an oppressive regime. A genocide survivor here is defined by an individual who survived or escaped a genocide in their country of origin. Currently, there are no evidence-based treatments developed specifically for the syndrome associated with Intergenerational trauma. This study aims to assess the safety and tolerability of psilocybin-assisted therapy, and assess the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

Participants will be asked to attend one or more screening visits to assess eligibility. If eligible, participants will be treated with two separate doses of the study medication, Psilocybin, 3-4 weeks apart. This is an open-label research study, meaning all participants will receive Psilocybin (25mg). Two trained clinical practitioners will work with participants across preparation, dosing, and integration processes. Participants will complete assessments throughout the study until their participation has ended. Safety measures are in place to check the overall health and well-being of participants

Participation will consist of:

  • Screening Period (up to 4 weeks): Phone screen, informed consent, eligibility assessment.
  • Tapering \& Enrollment Period (variable): Enrollment, supervised medical tapering where necessary as discussed with the study doctor, biomarker collection and psychometric baseline assessments.
  • Preparatory \& Treatment Period (up to 14 weeks): Three preparatory sessions with study clinicians, assessments; two dosing days at least three weeks apart, three weekly integration sessions with study clinicians following each dose, a 72-hour check-in call after each dosing day, assessments.
  • Follow-Up Period (up to 5 weeks): Follow-up one month after final integration session, assessments, clinical evaluation, biomarker collection
03

Conditions studied

  • Psychological Stress
  • Depression
  • Anxiety

Keywords

  • psilocybin
  • psilocybin-assisted therapy
  • intergenerational trauma
  • psychedelic
  • stress
  • genocide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at least 18 years old at time of signing the .
  • Biological child of at least one parent who directly survived/escaped a genocide.
  • Evidence of intergenerational trauma-related symptoms, as determined by the modified Parental PTSD Questionnaire (mPPQ).
  • Meet diagnostic criteria for a depressive, anxiety, trauma-, or stressor-related disorder on the Structured Clinical Interview for (SCID-5).
  • of ≥ 17.
  • Capable of providing written informed consent and complying with study procedures.
  • If of , willing to use a highly effective method of throughout study participation. Participants who can father a child and have partners of reproductive potential must also agree to use effective contraception throughout study participation.
  • Willing and medically appropriate to discontinue serotonergic medications before study treatment and remain off such medications throughout study participation, as determined by the study physician in consultation with the participant's treating healthcare provider.
  • Fluent in speaking and reading English.
  • Able to swallow pills.
  • Agree to have all study visits (both in-person and remote) recorded with audio and video.
  • Able to provide a contact person who can be reached by investigators in the event of the participant becoming unwell or unreachable.
  • Must agree to inform the investigators within 48 hours of any medical conditions and procedures.
  • Agree to release relevant medical and psychiatric records for eligibility determination and safety monitoring.
  • Agree to comply with protocol-specified lifestyle restrictions and study requirements.

Safety note (not incl./excl. criteria): Note to Potential Participants: Individuals interested in this study should not stop, taper, or otherwise change prescribed medications before speaking with the study team. Any medication changes required for study participation will be evaluated by qualified study clinicians and, when appropriate, coordinated with the participant's treating healthcare provider.

Exclusion criteria

Exclusion Criteria:

  • Individual was directly exposed to the genocide.
  • Current or recent illicit drug or prescription drug substance use disorder (excluding cannabis and tobacco use disorders), as determined by criteria and clinical assessment.
  • Current or recent alcohol or cannabis use disorder that, in the opinion of the investigator, may interfere with safe participation or study outcomes.
  • Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months.
  • Recent use of psychedelic substances.
  • Recent non-medical or illicit use of ketamine.
  • Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder.
  • Current serious suicide risk, recent suicidal behavior, or clinician concern that the participant poses a risk to self or others.
  • Acute, severe, or unstable medical illness, including clinical or laboratory evidence of severe renal and/or hepatic impairment.
  • Any physical or intellectual disability adversely affecting ability to complete assessments.
  • Current pregnancy or currently chest/breastfeeding.
  • Any abnormal laboratory test result, as determined by the investigator.
  • Current treatment with medications with study treatment that cannot be safely tapered, discontinued, or substituted in accordance with the protocol.
  • History of clinically significant or other clinically significant cardiac conduction abnormality.
  • Use of medications known to prolong the QT interval that cannot be safely discontinued.
  • Any congenital prolongation of the QT interval or a family history of long QT syndrome.
  • A family history in a first-degree relative of psychosis/schizophrenia or related disorders as assessed by clinical interview with Study MD.
  • A first-degree family history of bipolar disorder as assessed by clinical interview with Study MD.
  • Current anorexia nervosa or bulimia nervosa as determined by DSM-V criteria using the SCID-V.
  • A clinically meaningful history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication.
  • Preexisting clinically meaningful cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension that may be worsened/exacerbated by elevated blood pressure or heart rate.
  • Neurological conditions including stroke, (TIA), epilepsy, neurodegenerative disease, brain tumor, or other neurological disorders that would impact participation in the trial.
  • Insulin-dependent diabetes.
  • Vital sign abnormalities at screening that exceed protocol-defined safety thresholds.
  • to psilocybin.
  • Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin.
  • Positive toxicology findings not adequately explained by prescribed medications or approved treatment regimens.
  • Clinically meaningful abnormalities on screening (ECG).
  • Fall risk if not mitigated by assistance from study staff.
  • Can't identify a support person who will be able to accompany them home and stay the night with them post experimental session.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Psilocybin-Assisted Therapy

    Offspring of genocide survivors with mood and anxiety disorders will undergo weekly therapy sessions and will be given 2 doses of psilocybin at least 3 weeks apart.

    Drug: Psilocybin · Behavioral: Integration sessions

Interventions

  • Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists

    Also known as: Psilocybin-Assisted Therapy

  • BehavioralIntegration sessions

    weekly integration sessions (therapy) for 6 weeks

06

What researchers measure

Primary outcomes

  1. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicide risk as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) - Full Scale: 0 - 6. Higher scores indicate increased risk of suicide.

    Time frame: up to 23 weeks

  2. Brief Psychiatric Rating Scale (BPRS-6)

    Brief Psychiatric Rating Scale (BPRS-6) - Full Scale: 0 - 36. Higher scores indicate the number and severity of psychiatric symptoms.

    Time frame: up to 23 weeks

Secondary outcomes

  1. Change in Depression, Anxiety, and Stress Symptoms Scale (DASS-21)

    Change in Depression, Anxiety, and Stress Symptoms Scale (DASS-21) score. Stress scale - Subscale: 0 - 42 Anxiety scale - Subscale: 0 - 42 Depression scale - Subscale: 0 - 42 Full scale: 0 - 126 Higher scores indicate higher severity of symptomology.

    Time frame: Baseline (V0), Weeks Week 4-10 (V7), Week 6-15 (V11), Week 23(V12)

  2. Change in Parental PTSD Questionnaire (PPQ)

    Change in Parental PTSD Questionnaire (PPQ) score. Full Scale: 11 - 55 Higher scores indicate more negatively affected by perception of parents' trauma

    Time frame: Baseline (V0) and Week 23 (V12)

  3. Change in Resilience Scale for Adults (RSA)

    Change in Resilience Scale for Adults (RSA) score. Full Scale: 33- 231 Higher scores indicate higher resilience

    Time frame: Baseline (V0) and at Week 23 (V12)

07

Study locations

1 of 1 sites recruiting
  • The Parsons Research Center for Psychedelic Healing
    New York, New York 10025, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No plans to at this time

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for May 2029, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 27, 2025
StartEst.
Aug 28, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
Jan 2, 2030
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06899165
Lead sponsor
Rachel Yehuda
Responsible party
Rachel Yehuda (Director of the Parsons Research Center for Psychedelic Healing, Professor of Psychiatry at Mount Sinai, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Mar 27, 2025
Start date
Aug 28, 2026 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
Jan 2, 2030 (estimated)
Last update
Aug 13, 2026

Study contacts

Lauren Lepow, MD, PhD
Contact
lauren.lepow@mountsinai.org
646-438-5044
Evelyn Alkin, MA
Contact
IntergenStudy@mssm.edu
929-489-7440
Rachel Yehuda, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion